We conducted a systematic review of studies published before March 2007 in which a PSA dynamic (velocity or doubling time) was calculated in patients before definitive treatment, a subsequent event ...

A detectable level of prostate-specific antigen (PSA) is the first indicator of recurrent prostate cancer after radical prostatectomy. In a new Mayo Clinic study, the concept of PSA doubling time is ...

Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model. Background: Currently, there are few well-validated data of PSA kinetics (PSA doubling time [PSADT] ...

A simple and reproducible test is still needed to identify in newly diagnosed stage A CLL patients, those patients with a higher risk of progressive disease. Toward this end, we prospectively ...